10-K: Incannex Healthcare Reports FY25 Losses, Advances Drug Pipeline

Incannex Healthcare Inc. reported a significant increase in net loss for fiscal year 2025, driven by financing activities, while advancing its lead drug candidates IHL-42X and PSX-001 through clinical trials.

Summary

• Total comprehensive loss for the fiscal year ended June 30, 2025, was $46.7 million, a significant increase from $18.5 million in the prior fiscal year.
• Net cash outflows from operating activities decreased to $12.5 million in FY25 from $15.8 million in FY24.
• Accumulated comprehensive losses stood at $157.6 million as of June 30, 2025.
• Cash and cash equivalents were $15.0 million as of June 30, 2025, increasing to $73.4 million unrestricted cash and cash equivalents as of September 29, 2025, following recent share issuances.
• IHL-42X (Obstructive Sleep Apnea) Phase 2 portion of the RePOSA study completed in July 2025, demonstrating statistically and clinically significant reductions in AHI (up to 83% for high-dose, 79% for low-dose) and improved patient-reported outcomes; the drug was well-tolerated.
• PSX-001 (Generalized Anxiety Disorder) Phase 2 PsiGAD1 trial completed in August 2025, showing statistically meaningful reductions in Hamilton Anxiety Rating Scores (average 12.8 points) and 24% full disease remission; the treatment was well-tolerated.
• IHL-675A (Rheumatoid Arthritis) Australian Phase 2 clinical trial was terminated due to patient recruitment challenges, yielding insufficient data; a U.S. IND opening study for a Phase 2 trial is being planned.
• R&D tax incentives decreased by $9.7 million to $1.8 million for FY25.
• General and administrative expenses decreased by $4.0 million to $13.1 million for FY25, primarily due to lower equity compensation.
• Significant financial activities in FY25 included a $21.9 million change in fair value of warrant liabilities, a $1.5 million loss on debt extinguishment, and a $1.1 million ELOC commitment fee.
• The company received a Nasdaq notice on April 23, 2025, for non-compliance with the minimum bid price requirement, with an initial grace period expiring October 20, 2025.
• A material weakness in internal control over financial reporting was identified as of June 30, 2025, related to the documentation of accounting policies and procedures.
• The company increased the capacity of its at-the-market (ATM) offering program by an additional $100 million on July 24, 2025, to enhance financial flexibility.
• A 50:50 joint venture with Mind Medicine Australia (MMA) was announced on June 17, 2025, to operate a psychedelic-assisted therapies services clinic in Melbourne, Australia.

Sentiment

Score: 4

Explanation: While the company has reported promising Phase 2 clinical trial results for IHL-42X and PSX-001, addressing significant unmet medical needs, these positives are currently overshadowed by substantial financial losses, a significant decrease in R&D tax incentives, the termination of a Phase 2 trial for IHL-675A due to recruitment issues, and a Nasdaq minimum bid price deficiency. The identified material weakness in internal controls also adds to operational risk. The company's ability to secure future funding and navigate complex regulatory pathways for controlled substances remains critical.

Positives

• IHL-42X Phase 2 RePOSA study for Obstructive Sleep Apnea (OSA) demonstrated statistically and clinically significant improvements, with maximum AHI reductions of up to 83% for the high-dose group and 79% for the low-dose group.
• IHL-42X was observed to be well-tolerated across both lowand high-dose cohorts, with no serious adverse events reported.
• PSX-001 Phase 2 PsiGAD1 trial for Generalized Anxiety Disorder (GAD) met its primary endpoint, showing statistically meaningful reductions in HAM-A scores (average 12.8 points) and 24% full disease remission, which was five times higher than placebo.
• PSX-001 was observed to be well-tolerated with no serious adverse events reported in the PsiGAD1 trial, and no signs of increased suicidality, psychosis, or prolonged psychological distress were observed.
• The FDA cleared the Investigational New Drug (IND) application for PSX-001, authorizing a multi-jurisdiction Phase 2b clinical trial.
• IHL-42X bioavailability/bioequivalence (BA/BE) clinical trial confirmed bioavailability and a pharmacokinetic (PK) profile similar to reference listed drugs, potentially facilitating the FDA 505(b)(2) regulatory pathway.
• IHL-675A Phase 1 clinical trial showed the drug was well-tolerated and its active pharmaceutical ingredients (APIs) were bioavailable, with trends suggesting potentially advantageous uptake profiles.
• The company formed a 50:50 joint venture with Mind Medicine Australia (MMA) to operate a psychedelic-assisted therapies services clinic in Melbourne, Australia, representing a strategic advancement in its commercialization model.
• The at-the-market (ATM) offering program capacity was increased by $100 million, enhancing financial flexibility and providing an efficient mechanism to access capital.
• Current cash balances and anticipated cash flows provide sufficient resources to meet obligations and sustain operations for at least one year from the financial statements' issuance date.
• Management believes there is no longer substantial doubt about the company's ability to continue as a going concern.

Negatives

• Total comprehensive loss significantly increased to $46.7 million in FY25 from $18.5 million in FY24, indicating worsening financial performance.
• Accumulated comprehensive losses reached $157.6 million as of June 30, 2025.
• The R&D tax incentive decreased substantially by $9.7 million to $1.8 million in FY25, impacting cash resources.
• The Australian Phase 2 clinical trial for IHL-675A was terminated due to patient recruitment challenges, resulting in insufficient data to draw conclusions on safety or efficacy.
• The company incurred significant negative financial impacts from financing activities, including a $21.9 million change in fair value of warrant liabilities, a $1.5 million loss on debt extinguishment, and a $1.1 million ELOC commitment fee.
• The common stock closing bid price has consistently been below $1.00 per share since early March 2025, leading to a Nasdaq minimum bid price deficiency notice and risk of delisting.
• A material weakness in internal control over financial reporting was identified as of June 30, 2025, related to the documentation of accounting policies and procedures.
• The company has a history of operating losses and does not expect to generate material revenues until drug candidates are approved, which is several years away, if ever.
• Reliance on third-party manufacturers and CROs exposes the company to risks of supply limitations, quality issues, and delays.
• Drug candidates containing controlled substances (cannabinoids, psilocybin) are subject to strict and evolving regulations, potentially delaying launch or affecting the legality of investments in certain jurisdictions.
• The biopharmaceutical industry is highly competitive, with many competitors having significantly greater financial, manufacturing, marketing, and R&D resources.
• Uncertainty exists regarding the acceptance of non-U.S. clinical trial data by U.S. regulatory agencies, potentially requiring additional costly and time-consuming trials.
• The company is exposed to product liability claims, which could result in substantial costs and reputational harm.
• Fluctuations in exchange rates may adversely affect operating results, as the company operates globally and reports in USD while its functional currency is AUD for some subsidiaries.
• There is a scarcity of experienced professionals in the industry, posing challenges for attracting and retaining key personnel.
• The company's information technology systems are vulnerable to cybersecurity threats, which could lead to disruptions, data loss, and significant expenses.
• No cash dividends are anticipated on common stock in the foreseeable future, meaning capital appreciation is the sole source of gain for stockholders.
• Future sales of common stock or convertible securities could further dilute existing stockholders' ownership interests and depress the stock price.
• The company is and may continue to be subject to short-selling strategies, which could drive down the market price of its common stock.

Risks

• We have a history of operating losses and may not achieve or maintain profitability in the future.
• Our ability to achieve profitability depends on the successful development of our drug candidates.
• We rely on R&D tax incentives to provide resources to conduct our business operations. If the amount of R&D tax incentives decreases, our results of operations and cash resources may be materially affected.
• We expect that we will need substantial additional funding to continue the development of our drug candidates. If we are unable to raise capital when needed or to do so on terms that are favorable to us, we could be forced to again delay, reduce or eliminate our development programs or commercialization efforts or reduce or scale back our operations.
• We may be unable to maintain the listing of our shares of common stock on the Nasdaq Capital Market.
• If we do not obtain the necessary regulatory approvals, we will be unable to commercialize our drug candidates.
• Clinical drug development involves a lengthy and expensive process with uncertain outcomes. The results of earlier preclinical studies or trials may not be predictive of the results of later clinical trials. Clinical trials are difficult to design and implement, and any of our clinical trials could produce unsuccessful results or fail at any stage in the process.
• Topline, interim or preliminary data from our trials may not be representative of final results.
• We rely on third parties to conduct our preclinical and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.
• Even if we receive marketing approval of a drug candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products, if approved.
• Our drug candidates will be subject to controlled substance laws and regulations. Failure to receive necessary approvals may delay the launch of our drug candidates and failure to comply with these laws and regulations may adversely affect the results of our business operations.
• The production and sale of our drug candidates may be considered illegal or may otherwise be restricted due to the use of controlled substances, which may have consequences for the legality of investments from international jurisdictions.
• The markets for the target indications for our drug candidates are competitive and certain of our competitors have more advanced candidates in their respective pipelines. While we believe our drug candidates have expected benefits that may overcome these advantages, our efforts to prevail as compared to our competitors may not be successful.
• Our R&D efforts will be jeopardized if we are unable to retain key personnel and cultivate key academic and scientific collaborations.
• Our business is subject to complex and evolving U.S. federal and state, and international laws and regulations, imposing obligations on how we collect, use, disclose, store and process personal data. We are also subject to information security policies and contractual obligations relating to privacy and data protection, including the use, processing, and cross-border transfer of personal data. The actual or perceived failure by us or vendors to comply with these laws and regulations, policies and contractual obligations could harm our business and/or reputation, and subject us to significant fines and liability.
• We are exposed to fluctuations in exchange rates which may adversely affect our operating results.
• Our success depends on our ability to protect our intellectual property and our proprietary technology, and we may not be able to protect our intellectual property rights throughout the world.
• If we are unable to obtain and maintain patent protection for any drug candidates, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any drug candidates we may develop, and our technology may be adversely affected.
• We are currently exploring a patent protection strategy for our candidate PSX-001. If these efforts are unsuccessful, we may not be able to obtain intellectual property protection for this candidate.
• The price of our common stock has been and may continue to be highly volatile, which may make it difficult for stockholders to sell our common stock when desired or at attractive prices.
• Our common stock could be further diluted as the result of the issuance of additional shares of common stock, warrants, options or other convertible securities.
• Future sales of shares of our common stock in the public market, or the perception that such sales could occur, has in the past and could in the future cause our stock price to fall.
• We are and may continue to be subject to short-selling strategies.
• We could become exposed to product liability claims that could adversely affect our business.
• Product shipment delays could have a material adverse effect on our business, results of operations and financial condition.
• Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, substantial civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
• Changes in U.S. healthcare law and implementing regulations, as well as changes in healthcare policy, may impact our business in ways that we cannot currently predict and may harm our business and results of operations.
• Our drug candidates contain cannabinoid and psychedelic substances, the use of which may generate public controversy. Adverse publicity or public perception regarding our current or future drug candidates may negatively influence the success of these therapies.
• Our existing and any future joint ventures may limit our flexibility with jointly owned investments and we may not realize the benefits we expect from these arrangements.
• Intellectual property rights of third parties could adversely affect our ability to commercialize our drug candidates, such that we could be required to litigate with or obtain licenses from third parties in order to develop or market our drug candidates.
• Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
• We could be required to incur significant expenses to obtain our intellectual property rights, and we cannot ensure that we will obtain meaningful patent protection for our drug candidates.
• We may not have sufficient patent term or regulatory exclusivity protections for our drug candidates to effectively protect our competitive position.
• If we are unable to obtain and maintain patent protection for any drug candidates, our competitors could develop and commercialize products or technology similar or identical to ours, and our ability to successfully commercialize any drug candidates we may develop, and our technology may be adversely affected.
• Price controls may be imposed in non-U.S. markets, which may negatively affect our future profitability.
• U.S. investors may have difficulty enforcing civil liabilities against our directors or members of senior management.
• Certain provisions of our amended and restated certificate of incorporation may discourage, delay or prevent a change in control of our company and, therefore, depress the trading price of our securities.
• We do not anticipate paying any cash dividends on our capital stock in the foreseeable future; capital appreciation, if any, will be your sole source of gain as a holder of our common stock.
• If securities or industry analysts do not publish, or cease publishing, research or reports, or publish unfavorable research or reports, about us, our business or our market, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.
• Having availed ourselves of scaled disclosure available to smaller reporting companies, we cannot be certain if such reduced disclosure will make our common stock less attractive to investors.
• We may become involved in securities litigation that could materially divert management's attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages.
• Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us.

Future Outlook

We expect R&D expenses to increase substantially in the foreseeable future as drug candidates advance into later stages of development. We anticipate needing substantial additional funding through equity sales, debt financings, or strategic collaborations. We believe current cash balances and anticipated cash flows provide sufficient resources for at least one year. Our strategy includes pursuing FDA approval for lead drug candidates and then expanding into the European Union, United Kingdom, Japan, Australia, and Canada to maximize global commercial potential. We also aim to seek streamlined regulatory pathways, including FDA expedited review programs and the 505(b)(2) pathway, and maintain a strong intellectual property portfolio.

Management Comments

• Our mission is to advance novel therapies, leveraging evidence-based innovation, with the potential to transform the lives of people suffering from serious, chronic conditions and unmet medical needs.
• We aim to maximize value to our stockholders and to provide important new treatment options to patients in need of new therapeutic options.
• We and our consultants and advisors believe that each of our lead drug candidates may be eligible to qualify for one or more FDA expedited review programs.
• Management believes inflation has not had a material impact on our operations or financial condition.
• Management further believes that our operations are not currently subject to seasonal influences due to our current lack of marketed products.
• As of the date of this Annual Report, we believe there is no longer substantial doubt about our ability to continue as a going concern.

Industry Context

We operate in the highly competitive biopharmaceutical industry, focusing on serious chronic diseases with limited or inadequate treatment options. Our strategy involves developing combination drug therapies using synthetic cannabinoids and psychedelic agents, an emerging area in mental health and inflammatory conditions. The estimated global market for OSA medical devices is approximately US$8.2 billion (7.33% CAGR from 2024-2029), GAD treatments in the U.S. reached US$21 billion in 2023, and the U.S. rheumatoid arthritis market was US$25.37 billion in 2023, projected to exceed US$31.58 billion by 2033. Key competitors include Apnimed (OSA), Cybin, Otsuka, Sunovion, Mind Medicine (GAD), and major pharmaceutical companies like Pfizer, Abbvie, and Amgen for rheumatoid arthritis. The regulatory landscape for controlled substances, such as marijuana and psilocybin, is evolving, with ongoing discussions at the DEA regarding rescheduling, which could impact the development and commercialization of our drug candidates.

Comparison to Industry Standards

• IHL-42X's observed AHI reductions (up to 83% for high-dose, 79% for low-dose) in the Phase 2 RePOSA study are significant, especially when compared to the low patient compliance (50% discontinuation within one year) associated with the current standard of care, positive airway pressure (PAP) devices, for OSA.
• Unlike tirzepatide (Zepbound), which is approved for obese OSA patients, IHL-42X targets the broader OSA patient population, including the estimated greater than 67% who are non-obese, addressing a significant unmet need not covered by existing pharmacological options.
• PSX-001's Phase 2 PsiGAD1 trial demonstrated a 24% full disease remission rate for GAD, which is five times higher than placebo, suggesting a potentially superior efficacy profile compared to conventional first-line treatments like SSRIs/SNRIs that often have delayed onset of action, poor adherence rates, and substantial side effects.
• The fact that two psilocybin third-party research programs for depression have received breakthrough therapy designation from the FDA indicates a growing regulatory acceptance and industry trend towards psychedelic-assisted therapies, aligning with PSX-001's development pathway.
• IHL-675A's fixed-dose combination of CBD and hydroxychloroquine sulfate is designed to act synergistically, potentially allowing for lower doses of each constituent drug, which could reduce the known risks associated with cumulative hydroxychloroquine dose without sacrificing efficacy, a potential advantage over existing monotherapies for inflammatory conditions.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business.

Related Party Transactions

• There were no amounts payable to any related parties as of June 30, 2025 and 2024.

Stakeholder Impact

• Shareholders face potential for significant dilution from future equity raises, stock price volatility, risk of Nasdaq delisting, and no anticipated cash dividends, with short-selling strategies potentially exacerbating stock price declines.
• Patients stand to benefit from potential new treatment options for Obstructive Sleep Apnea (OSA), Generalized Anxiety Disorder (GAD), and inflammatory conditions if drug candidates are successfully developed and approved.
• Employees are impacted by intense competition for qualified personnel in the specialized industry, making the ability to attract and retain key talent crucial for R&D efforts and overall business success.
• Regulators (FDA, DEA, EMA, MHRA, TGA) are critical stakeholders as ongoing compliance with their complex and evolving requirements is essential for drug development, clinical trials, and commercialization.
• Third-party partners, including Contract Research Organizations (CROs) and Contract Manufacturing Organizations (CMOs), are vital for clinical trials and manufacturing, with their performance directly influencing the company's ability to advance its pipeline.
• The investment community will closely monitor financial results, clinical trial outcomes, regulatory progress, and the resolution of Nasdaq compliance issues, all of which will significantly influence investor sentiment and analyst coverage.

Next Steps

• Finalizing arrangements for an End of Phase 2 meeting with the FDA for IHL-42X to obtain guidance on planned next steps, including pivotal Phase 3 trial design.
• Preparing to initiate a multi-jurisdiction Phase 2b clinical trial for PSX-001 in 2026.
• Developing a strategy for an IND opening study to investigate the safety and efficacy of IHL-675A in patients diagnosed with rheumatoid arthritis in the United States.
• Continuing to expand the intellectual property estate by filing patent applications directed to compositions, methods of use, treatment and patient selection, formulations, and manufacturing processes.
• Retaining flexibility to explore strategic partnerships, licensing agreements, and collaboration opportunities to maximize the value of the pipeline.
• Remediating the material weakness in internal control over financial reporting by hiring qualified internal control personnel or consultants, developing written policies and procedures, and conducting internal control training.
• Potentially completing a reverse stock split in an effort to regain compliance with Nasdaq's minimum bid price requirements.
• Continuing to plan for additional capital through the sale of common stock in public offerings and/or private placements, debt financings, or through other capital sources.

Key Dates

Recommendation

While the company has reported promising Phase 2 clinical trial results for IHL-42X and PSX-001, addressing significant unmet medical needs, these positives are currently overshadowed by substantial financial losses, a significant decrease in R&D tax incentives, the termination of a Phase 2 trial for IHL-675A due to recruitment issues, and a Nasdaq minimum bid price deficiency. The identified material weakness in internal controls also adds to operational risk. The company's ability to secure future funding and navigate complex regulatory pathways for controlled substances remains critical. Investors should hold to monitor the progress of pivotal Phase 3 trials, the resolution of Nasdaq compliance, and the effectiveness of remediation efforts for internal controls, as these factors will significantly influence future valuation.

Keywords

Biopharmaceutical, Clinical-stage, Obstructive Sleep Apnea, OSA, Generalized Anxiety Disorder, GAD, Rheumatoid Arthritis, Inflammatory Conditions, IHL-42X, PSX-001, IHL-675A, Dronabinol, Acetazolamide, Psilocybin, Cannabidiol, Hydroxychloroquine, SEC filing, 10-K, Nasdaq, Clinical trials, Drug development, Regulatory approval, FDA, EMA, MHRA, R&D, Financial results, Operating losses, Capital raise, Intellectual property, Controlled substances, Healthcare reform, Biopharma, Biotech